BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31777606)

  • 41. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.
    Kavalieris L; O'Sullivan PJ; Suttie JM; Pownall BK; Gilling PJ; Chemasle C; Darling DG
    BMC Urol; 2015 Mar; 15():23. PubMed ID: 25888331
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:
    Mijnes J; Veeck J; Gaisa NT; Burghardt E; de Ruijter TC; Gostek S; Dahl E; Pfister D; Schmid SC; Knüchel R; Rose M
    Clin Epigenetics; 2018; 10():15. PubMed ID: 29445424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
    Friedrich MG; Weisenberger DJ; Cheng JC; Chandrasoma S; Siegmund KD; Gonzalgo ML; Toma MI; Huland H; Yoo C; Tsai YC; Nichols PW; Bochner BH; Jones PA; Liang G
    Clin Cancer Res; 2004 Nov; 10(22):7457-65. PubMed ID: 15569975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.
    Liu C; Shi B; Hao C; Wang Q; Lv Q; Xing N; Shou J; Qu L; Gao Y; Qin C; Zhao J; Shou C
    Oncotarget; 2016 Jul; 7(28):43432-43441. PubMed ID: 27223068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.
    Connell SP; O'Reilly E; Tuzova A; Webb M; Hurst R; Mills R; Zhao F; Bapat B; Cooper CS; Perry AS; Clark J; Brewer DS
    Prostate; 2020 May; 80(7):547-558. PubMed ID: 32153047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive value of gene methylation for second recurrence following surgical treatment of first bladder recurrence of a primary upper-tract urothelial carcinoma.
    Guan B; Xing Y; Xiong G; Cao Z; Fang D; Li Y; Zhan Y; Peng D; Liu L; Li X; Zhou L
    Oncol Lett; 2018 Jun; 15(6):9397-9405. PubMed ID: 29805663
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
    Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative Analysis of Urine Fractions for Optimal Bladder Cancer Detection Using DNA Methylation Markers.
    Hentschel AE; Nieuwenhuijzen JA; Bosschieter J; Splunter APV; Lissenberg-Witte BI; Voorn JPV; Segerink LI; Moorselaar RJAV; Steenbergen RDM
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32252299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic verification of bladder cancer-associated tissue protein biomarker candidates in clinical urine specimens.
    Tsai CH; Chen YT; Chang YH; Hsueh C; Liu CY; Chang YS; Chen CL; Yu JS
    Oncotarget; 2018 Jul; 9(56):30731-30747. PubMed ID: 30112103
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer.
    Scher MB; Elbaum MB; Mogilevkin Y; Hilbert DW; Mydlo JH; Sidi AA; Adelson ME; Mordechai E; Trama JP
    J Urol; 2012 Dec; 188(6):2101-7. PubMed ID: 23083854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer.
    Huang S; Kou L; Furuya H; Yu C; Goodison S; Kattan MW; Garmire L; Rosser CJ
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1361-6. PubMed ID: 27383773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bronchial biopsy specimen as a surrogate for DNA methylation analysis in inoperable lung cancer.
    Um SW; Kim HK; Kim Y; Lee BB; Kim D; Han J; Kim H; Shim YM; Kim DH
    Clin Epigenetics; 2017; 9():131. PubMed ID: 29270240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes.
    Pietrusiński M; Kȩpczyński Ƚ; Jȩdrzejczyk A; Borkowska E; Traczyk-Borszyńska M; Constantinou M; Kaƚużewski B; Borowiec M
    Cancer Biomark; 2017; 18(1):47-59. PubMed ID: 27814275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.
    Lissa D; Ishigame T; Noro R; Tucker MJ; Bliskovsky V; Shema S; Beck JA; Bowman ED; Harris CC; Robles AI
    Lung Cancer; 2018 Aug; 122():151-159. PubMed ID: 30032824
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epigenetic alterations of adenomatous polyposis coli (APC), retinoic acid receptor beta (RARβ) and survivin genes in tumor tissues and voided urine of bladder cancer patients.
    Berrada N; Amzazi S; Ameziane El Hassani R; Benbacer L; El Mzibri M; Khyatti M; Chafiki J; Abbar M; Al Bouzidi A; Ameur A; Attaleb M
    Cell Mol Biol (Noisy-le-grand); 2012 Sep; Suppl.58():OL1744-51. PubMed ID: 22992440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic value of differentially methylated gene profiles in bladder cancer.
    Yang Z; Liu A; Xiong Q; Xue Y; Liu F; Zeng S; Zhang Z; Li Y; Sun Y; Xu C
    J Cell Physiol; 2019 Aug; 234(10):18763-18772. PubMed ID: 30953370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.